Sanofi

Aventis Pharma S.a.

Institut National De La Sante Et De La Recherche Medicale

Catherine Prades

Tarik Dabdoubi

Cendrine Lemoine

Béatrice Cameron

Ronnie Rong Wei

Gary J Nabel

Ercole Rao

Christian Beil

Ling Xu

Zhi-Yong Yang

Lan Wu

Edward Seung

Marie-Françoise Rosier-Montus

Seng H Cheng

Joerg Thomas Regula

Huawei Qiu

Alain Fournier

Christian Lange

Yunxiang Zhu

William Harold Brondyk

Patrice Denefle

Timothy D Connors

Laurent Pradier

Alexis Brice

Jochen Beninga

Hongmei Zhao

Joerg Birkenfeld

Olga Corti

Yangde Chen

Catherine Devaud

Leila Sevigny

Isabelle Arnould-Reguigne

Dietmar Hoffmann

Zhen Xing

Maureen Magnay

Tristan Magnay

Francis Blanche

Michael C Dean

Beatrice Cameron

Rando L Allikmets

Alan Thomas Remaley

Marie Rosier

Pierre Fons

Jean-Pascal Herault

Nicolas Duverger

Bryan H Brewer

Frederique Dol-Gleizes

Han Koutnikova

Laurent Naudin

Sylvia Santamarina-Fojo

Hana Koutnikova

Isabelle Arnould

Ronnie Wei

Provided herein are trispecific and/or trivalent binding proteins comprising four polypeptide chains that form three antigen binding sites that specifically bind one or more target proteins, wherein a first pair of polypeptides forming the binding protein possess dual variable domains having a cross-over orientation, and wherein and a second pair of polypeptides possess a single variable domain forming a single antigen binding site. In some embodiments, the binding proteins comprise a binding site that binds a CD28 polypeptide, a binding site that binds a CD3 polypeptide, and a binding site that binds a third polypeptide, such as a tumor target protein. In some embodiments, the binding proteins comprise four polypeptide chains that form three antigen binding sites that specifically bind one or more HIV target proteins. The disclosure also relates to methods for making trispecific and/or trivalent binding proteins and uses of such binding proteins.

Trispecific binding proteins, methods, and uses thereof

The disclosure provides methods of treating viral infection using trispecific binding proteins comprising four polypeptide chains that form three antigen binding sites that specifically bind a CD38 polypeptide (e.g., human and/or cynomolgus monkey CD38 polypeptides), a CD28 polypeptide, and a CD3 polypeptide.

Trispecific anti-CD38, anti-CD28, and anti-CD3 binding proteins and methods of use for treating viral infection

The disclosure provides binding proteins that bind CD38 polypeptides, e.g., human and cynomolgus monkey CD38 polypeptides. For example, the binding proteins can be monospecific, bispecific, or trispecific binding proteins with at least one antigen binding domain that binds a CD38 polypeptide. The disclosure also provides methods for making binding proteins that bind CD38 polypeptides and uses of such binding proteins.

Anti-CD38 antibodies and methods of use

Provided herein multispecific (e.g., bispecific) binding molecules comprising a first binding domain that binds an extracellular portion of dystroglycan and a second binding domain that binds laminin-2. Further provided herein are methods for making such binding molecules and uses of such binding molecules for treating and/or preventing alpha-dystroglycanopathies.

Multispecific binding molecules having specificity to dystroglycan and laminin-2

The present invention relates to a Robo1-Fc recombinant protein and to the use thereof for treating diseases in which a Slit protein is overexpressed, in particular cancer. The invention also relates to a composition including such a recombinant protein. Another aspect of the invention involves using a Robo1-Fc molecule as a diagnostic tool for detecting the overexpression of a molecule belonging to the Slit family in a patient.

Robo1-Fc fusion protein and use thereof for treating tumours

The present invention relates to novel compounds and their uses, in particular their pharmaceutical or diagnostic uses or their use as pharmacological targets. More particularly, the present invention relates to a novel protein, referred to as PAP1, as well as to novel peptides and compounds which are capable of modulating, at least partially, the activity of parkin.

Nucleic acids encoding a human PAP1 polypeptide

The present invention concerns a nucleic acid which is capable of regulating the transcription of the ABC1 gene, which is a causal gene for pathologies linked to a dysfunctioning of cholesterol metabolism, inducing diseases such as atherosclerosis. The invention also relates to nucleotide constructs comprising a polynucleotide which encodes a polypeptide or a nucleic acid of interest, placed under the control a regulatory nucleic acid for the ABC1 gene. The invention also relates to recombinant vectors, transformed host cells and nonhuman transgenic mammals comprising a nucleic acid which regulates the transcription of the ABC1 gene or an abovementioned nucleotide construct, as well as methods for screening molecules or substances which are capable of modifying the activity of the regulatory nucleic acid for the ABC1 gene.

Regulatory nucleic acid for the ABC1 gene, molecules modifying its activity and therapeutic uses

Compositions which can be used for regulating the activity of parkin

The present invention relates to nucleic acids corresponding to various exons of the ABCC11 gene as well as the cDNA encoding the novel full length of ABCC11 protein. The invention also relates to means for the detection of polymorphisms in general, and of mutations in particular, in the ABCC11 gene or in the corresponding protein produced by the allelic form of the ABCC11 gene.

Nucleic acids of the human ABCC11 gene, vectors containing such nucleic acids and uses thereof

Growing community of inventors

Choisy le Roi, France

Catherine Prades